Biopharmaceuticals at Teva

Getty Images/poba

Teva is investing in biopharmaceuticals as part of our long term strategy for the future, and to help patients around the world. We are focusing on treatments for the central nervous system, respiratory conditions, and in the field of oncology.

Biosimilars

Biopharmaceuticals are complex medicines made from living cells or organisms. They advance more treatment options for patients, some of whom suffer from untreated or undertreated conditions. They have the potential to deliver precise and personalized treatment.

Together with creating original biologic medicines, Teva is investing in biosimilars. These are highly similar versions of reference biological treatments.

A focus on biosimilars is a natural progression for Teva following our role in the development of the generic medicine industry over the past 40 years. They combine our strength in generics with our knowledge of complex medicine.

Biosimilars offer value-based treatment that is potentially less expensive than the originator biologic but similarly effective. For example, it is estimated that the use of biosimilars will save the US $54 billion over 10 years.

Together with creating original biologic medicines, Teva is investing in biosimilars. These are highly similar versions of reference biological treatments.
Getty Images/sanjeri

Products and pipeline

Teva has 5 biopharmaceuticals on the market today. In addition, we have approximately 20 original biologic and biosimilar programs in various phases of development, from discovery through to clinical and regulatory stages.

Many of these treatments will be produced in our new $500 million state-of-the-art biopharmaceutical plant in Ulm, Germany. 

The benefit that biopharmaceuticals will bring to patients is what inspires us as we invest in this exciting future. This new direction is integral to bringing more treatment options to patients, and supporting our mission to improve lives. 

Biopharmaceutical innovation will not take place overnight but we are committed to seeing the impact and results of our investment over the next decade.

Explore the magic of biosimilars watch here


Find out more

  • We’re hiring! Click here to discover the latest vacancies at Teva Pharmaceuticals.

You might also be interested

“This ‘invisible pandemic’ is one of the biggest global health challenges”

“This ‘invisible pandemic’ is one of the biggest global health challenges”

The secret to achieving our new environmental targets? Our people

The secret to achieving our new environmental targets? Our people

"Bringing more women and more diversity into our leadership makes us stronger."

"Bringing more women and more diversity into our leadership makes us stronger."

Meet the Expert: Professor Ruth Arnon

Meet the Expert: Professor Ruth Arnon

“The resilience of Teva’s operation never fails to surprise me”

“The resilience of Teva’s operation never fails to surprise me”

Improving access to medicines for 4000 children with cancer in Malawi

Improving access to medicines for 4000 children with cancer in Malawi

Teva sets ambitious long-term environmental goals

Teva sets ambitious long-term environmental goals

‘It has made a real difference’: Increasing access to medicines in Haiti

‘It has made a real difference’: Increasing access to medicines in Haiti

Rise of the Superbugs: 5 Key Questions Answered

Rise of the Superbugs: 5 Key Questions Answered

COVID-19 puts medicine supply security in Europe's spotlight

COVID-19 puts medicine supply security in Europe's spotlight